You are here

APT THERAPEUTICS, INC.

Company Information
Address
4041 Forest Park Avenue
SAINT LOUIS, MO 63108-3213
United States



Information

UEI: KCGRRQA5CKR4

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Multi-functional anti-thrombotic therapy for coronary microvascular obstruction

    Amount: $1,582,022.00

    Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong ABSTRACTAdjunctive antithrombotic treatment with dual antiplatelet therapy (aspirin + P2Y12 antagonist) plus anticoagulant (h ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Peripherally Acting Analgesic for Osteoarthritis Pain

    Amount: $259,576.00

    Principal Investigator/Program Director (Last, First, Middle: Ridong Chen Project Summary More than 25 million Americans suffer from chronic pain. In recent decades, due to the lack of other effective ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  3. Immunomodulatory Therapy for Neuropathic Pain

    Amount: $2,420,195.00

    Principal Investigator/Program Director (Last, First, Middle: Ridong ChenProject SummaryMore than 25 million Americans suffer from chronic pain. Due to the lack of other treatments, there has been an ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  4. Anti-inflammatory and Anti-diabetic Therapy for Metabolic Syndrome

    Amount: $300,000.00

    Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong AbstractMetabolic syndrome (MetS), affects more than 50 million people in the US alone. The current standard of care embodies ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  5. Combination treatment with tPA and IL2 analog for Stroke

    Amount: $344,933.00

    Principal Investigator Program DirectorLastFirstMiddleChenRidong AbstractDue to its narrow time window of administrationup tohours post symptomsandfold increased risk of intracranial hemorrhagemerelyo ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  6. Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody

    Amount: $300,000.00

    Principal Investigator Program DirectorLastFirstMiddleChenRidong Abstract InterleukinILimmunotherapy can result in remarkable long term responses in some cancer patients by stimulating the immune resp ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  7. Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade

    Amount: $299,794.00

    Principal Investigator Program DirectorLastFirstMiddleChenRidong Abstract The durable clinical efficacy of immune checkpoint inhibitors in a variety of cancers has demonstrated the tremendous potentia ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  8. Immunomodulatory Therapy for Neuropathic Pain

    Amount: $299,346.00

    Principal Investigator Program DirectorLastFirstMiddleRidong Chen Project SummaryNeuropathic pain can be difficult to treat with onlyof patients achieving meaningfulandgtpain reliefCurrent therapiese ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  9. Prevention of Post-MI Heart Failure with Immunomodulatory Therapy

    Amount: $337,602.00

    Principal Investigator Program DirectorLastFirstMiddleChenRidong AbstractIncidence and mortality from post myocardial infarctionMIheart failureHFare increasing and becoming a major health problem worl ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  10. Antithrombotic Therapy with No Bleeding Risk for PCI

    Amount: $1,902,274.00

    Adjunctive antithrombotic treatment with dual antiplatelet therapyaspirinP Yantagonistplus anticoagulantheparin or bivalirudinis a guideline mandated for percutaneous coronaryinterventionPCIpatientsDe ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government